Maze Therapeutics, Inc.
MAZE Nasdaq
SEC CIK 1842295
Follow Maze Therapeutics
Weekly email: filings, results
Revenue, last quarter
$0
Net income
−$48M
−59.4% vs same quarter last year
EPS, diluted
−$0.79
−19.7% vs same quarter last year
Operating cash flow
−$32.8M
−33.3% vs same quarter last year
Source: SEC XBRL filings · latest filing